secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001104659-25-121828
Event type: m_and_a
Sentiment:  negative
Materiality: 0.95
Item codes: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Therapeutics to merge with Yarrow Bioscience; Yarrow stockholders to own ~97% of combined company
--------------------------------------------------------------------------------

- Pro forma ownership: pre-Merger Yarrow stockholders ~97%, VYNE stockholders ~3%.
- Pre-Closing Dividend of ~$14.5M to $16.5M to VYNE stockholders prior to close.
- Two concurrent financings: Yarrow Series A preferred ~$100M and Pre-Closing PIPE ~$100M.
- Expected close Q2 2026; post-close board and officers designated by Yarrow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465925121828/0001104659-25-121828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465925121828/tm2533624d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-121828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer